MyFinsight
Home
Blog
About
Proceeds from offering,
net-Underwritten Offering
$351,325K
Proceeds from offering,
net-At The Market...
$13,580K
Proceeds from shares
issued under equity...
$878K
(302.75%↑ Y/Y)
Net cash provided by
financing activities
$364,569K
(167133.49%↑ Y/Y)
Canceled cashflow
$1,214K
Net increase
(decrease) in cash and cash...
-$110,311K
(-8627.14%↓ Y/Y)
Canceled cashflow
$364,569K
Maturities of investments
$136,438K
(-1.05%↓ Y/Y)
Accounts payable
$15,055K
(421.66%↑ Y/Y)
Non-cash interest
expense on liabilities...
$7,206K
(-30.50%↓ Y/Y)
Stock-based compensation
$3,365K
(-54.43%↓ Y/Y)
Loss from equity
method investment
-$319K
(95.34%↑ Y/Y)
Depreciation and
amortization expense
$156K
(-75.63%↓ Y/Y)
Payments of offering
costs associated with...
$1,214K
Net cash provided by
(used in) investing...
-$399,110K
(-527.75%↓ Y/Y)
Canceled cashflow
$136,438K
Net cash used in
operating activities
-$75,770K
(20.07%↑ Y/Y)
Canceled cashflow
$26,101K
Purchases of investments
$535,454K
(1121.05%↑ Y/Y)
Purchases of property and
equipment
$94K
(141.03%↑ Y/Y)
Other assets
$40,833K
(721.09%↑ Y/Y)
Net loss
-$40,622K
(56.07%↑ Y/Y)
Non-cash royalty revenue
related to the sales of...
$10,131K
(-53.17%↓ Y/Y)
Operating leases, net
$4,426K
(-20.68%↓ Y/Y)
Amortization of premiums
(discounts), net
-$3,570K
(-62.79%↓ Y/Y)
Accrued expenses
-$2,289K
(-158.10%↓ Y/Y)
Interest income
$9,346K
Loss before equity
method investment
-$40,303K
Loss from equity
method investment
-$319K
(95.34%↑ Y/Y)
Total non-operating
income (expense), net
$2,040K
Canceled cashflow
$7,306K
Loss before
provision for income taxes...
-$40,301K
Provision (benefit) for
income taxes
$2K
Canceled cashflow
$2,040K
Revenue
$10,131K
Non-cash interest
expense on liabilities...
$7,206K
(-30.50%↓ Y/Y)
Other income
(expense), net
-$100K
Loss from operations
-$42,341K
Canceled cashflow
$10,131K
Total operating costs
and expenses
$52,472K
Clinical development,
contract manufacturing...
$23,560K
Employee costs
$14,962K
Other operating costs
$7,095K
Other segment
expenses
$4,065K
Facilities costs
$2,790K
Rezpegaldesleukin
$22,389K
TNFR2Program
$735K
Discovery Research And
Other Programs
$436K
Back
Back
Cash Flow
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)
source: myfinsight.com